Initiation of Tocilizumab or Baricitinib Were Associated With Comparable Clinical Outcomes Among Patients Hospitalized With COVID-19 and Treated With Dexamethasone.

Front Pharmacol · 2022 · PMC9189358 · PMID 35707401

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

marginal significanceno p-value reported

Time to viral clearance (HR = 1.94, 95%CI 1.01-3.73, p = 0.048) was shorter in the tocilizumab group with marginal significance, compared to that of baricitinib.

also in 5,069 other papers

of marginal significanceno p-value reported

Tocilizumab users had a shorter time to viral clearance (HR = 1.94, 95%CI 1.01-3.73, p = 0.048) of marginal significance, compared to baricitinib users ( Table 2 ).

also in 464 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.